BioMedNewsBreaks

TuesdayMay 28, 2024 9:34 am

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters IR Agreement with IR Agency

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an investor relations services agreement with IR Agency LLC. According to the announcement, the agreement, which was effective May 22, 2024, outlines IR Agency’s responsibilities to communicate information about FSD Pharma to the financial community. That information could include company profiles and media distribution as well as building a digital community. The agreement is for one month, with services beginning on May 28, 2024; the contract notes that FSD Pharma will pay a fee of…

Continue Reading

WednesdayMay 22, 2024 3:28 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases

Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative disease. “The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity necessary for movement, cognitive function and more. Clene’s CEO, Rob Etherington, highlighted that CNM-Au8 is tailored to address the central nervous system needs, targeting diseases like ALS and MS… Clinical trials of CNM-Au8 have shown…

Continue Reading

WednesdayMay 22, 2024 3:02 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments

PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, recently took swift action to address a pressing medical situation unfolding in Malawi, East Africa. “The Ministry of Health (‘MOH’) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica’s dedication to mitigating the devastating impact of sleeping sickness and ensuring access to…

Continue Reading

WednesdayMay 22, 2024 2:44 pm

BioMedNewsBreaks — SOHM, Inc. (SHMN) Continues to Advance Groundbreaking Technology

SOHM (OTC: SHMN), a leading generic pharmaceutical and upstart biotechnology company, today announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. The technology holds the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The revolutionary new ABBIE system, due to SOHM’s committed, consistent and focused approach by lead scientists at its lab at UACI in Tucson, Arizona, is due to be sold as off-the-shelf kits in the third quarter of this year. “We are…

Continue Reading

TuesdayMay 21, 2024 3:40 pm

BioMedNewsBreaks — Astiva Health Fostering Proactive Environment Where Primary Care Thrives

Astiva Health is a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities. “Astiva Health is dedicated to enhancing the quality of medical care through a strong doctor-patient relationship with the success of its model hinging on knowledgeable, competent and hard-working primary care physicians (‘PCPs’) who play a pivotal role in the healthcare system… Astiva Health is dedicated to establishing a healthcare ecosystem where the best primary care doctors are not only rewarded for their expertise but also for their commitment to providing the best possible care… In addition, Astiva Health collaborates with more…

Continue Reading

TuesdayMay 21, 2024 1:27 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, will be spotlighted in an upcoming webinar, hosted by RedChip Companies. The event is slated for May 30, 2024, and will begin at 4:15 p.m. ET. Nutriband chair Serguei Melnik and CEO Gareth Sheridan will present during the event, which will provide key information for investors regarding current operations and upcoming milestones. To register for the event, visit https://ibn.fm/9REfQ To view the full press release, visit https://ibn.fm/mH9jC About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development…

Continue Reading

MondayMay 20, 2024 2:09 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Positive Study Data for Its AI Program

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter. Key findings from the analysis show that HeartBeam AI combined with VCG outperformed an expert panel reviewing single-lead ECGs and demonstrated a statistically significant 6% improvement in the detection of atrial flutter cases compared to an expert panel reviewing 12-lead ECGs. “The modern vectorcardiogram is nearly 100 years old, and yet we are cautiously…

Continue Reading

MondayMay 20, 2024 1:17 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company Showcase

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners. Climaco’s presentation is slated to begin at 1:40 p.m. ET on May 21, 2024. A live webcast will be available on the Events page of CNSP’s website. To view the full press release, visit https://ibn.fm/TQeLP About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company…

Continue Reading

MondayMay 20, 2024 11:47 am

BioMedNewsBreaks — NextPlat Corp’s (NASDAQ: NXPL) GTC Begins Sales of SpaceX’s Starlink as Authorized Reseller

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its subsidiary, Global Telesat Communications Ltd (“GTC”), through a new joint venture agreement with Pivotel Solutions Inc. (dba “Pulsar”) is now a global authorized reseller of SpaceX’s Starlink satellite-based connectivity products. Under the agreement as as an approved reseller, GTC will immediately begin offering Starlink connectivity services in the U.K. and other international markets serving mobile and maritime-based customers. Pulsar will provide GTC back-end systems support services on behalf of its new Starlink customers. “We are pleased to collaborate with Pulsar to begin offering SpaceX’s revolutionary Starlink, LEO-satellite based…

Continue Reading

ThursdayMay 16, 2024 1:56 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed in a potentially pivotal GBM study evaluating Berubicin with topline data expected in the first half of 2025. In addition, financial results showed a net loss for the quarter of approximately $3.5 million, down from an estimated $4.9 million net loss for the comparable period…

Continue Reading